Dr. Flowers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2003- University of WashingtonResidency, Internal Medicine, 1997 - 2000
Stanford University School of MedicineClass of 1997
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2020 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2022 - 2025
GA State Medical License 2003 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
American Board of Internal Medicine Medical Oncology- Join now to see all
Clinical Trials
- Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas Start of enrollment: 2023 Feb 23
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.Samuel Yamshon, Jean L Koff, Melissa C Larson, Brad S Kahl, Carla Casulo
American Journal of Hematology. 2025-02-07 - Phase II trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.Dai Chihara, Raphael E Steiner, Ranjit Nair, Lei Feng, Sairah Ahmed
Blood Advances. 2025-02-05 - Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Christopher R Flowers, Rachel W Anantha, Veronica Leautaud, Pinkal Desai, Chancellor E Donald
Blood Cancer Discovery. 2025-02-03
Press Mentions
MD Anderson Cancer Center and Myriad Genetics Sign Strategic AllianceJanuary 10th, 2025- MD Anderson and Myriad Genetics Partner on MRD Assay DevelopmentJanuary 8th, 2025
- MD Anderson and Myriad Genetics Join Forces to Assess Clinical Utility of Myriad’s Molecular Residual Disease AssayJanuary 7th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
